European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478- Jun 2026

When the laboratory’s fluorescent lights hummed to life at 07:00, Dr. Elena Varga already had the monograph open on her screen. It was the 0478 monograph — Tablets — the quiet scaffolding behind millions of doses crossing borders, dispensed in hospitals, bought at neighborhood pharmacies. To most, it was an obscure file name in the European Pharmacopoeia; to Elena it was a promise: consistent quality, safety and identity, written in a language of limits and methods.

Tablets must comply with standards for non-sterile preparations described in Ph. Eur. Chapter 5.1.4.

Elena had worked in regulatory affairs long enough to know how a single change could ripple outward. A tweak to an assay, stricter limits on impurities, or a new dissolution requirement could force reformulation, new stability studies, and additional validation runs. Yet that was the point. The Pharmacopoeia existed to adapt to evolving science, to close gaps where variability might otherwise find purchase. European Pharmacopoeia -ph. Eur.- Monograph Tablets -0478-

While it primarily covers standard oral tablets, the monograph explicitly segmentizes several distinct categories of tablets, each with tailored criteria:

Where disintegration confirms mechanical breakdown, dissolution testing measures the actual rate at which the active pharmaceutical ingredient (API) dissolves into a solution. Following modern policy updates by the EDQM Commission , an immediate-release solid dosage monograph requires a specific dissolution test to ensure in vivo bioequivalence and batch-to-batch consistency. 3. Uniformity of Dosage Units (Ph. Eur. 2.9.40) When the laboratory’s fluorescent lights hummed to life

To comply with Ph. Eur. 0478, tablets must pass a rigorous battery of tests. These tests ensure that the physical characteristics of the tablet translate into reliable therapeutic performance. 1. Uniformity of Dosage Units

While disintegration shows the tablet breaking apart, dissolution measures the rate at which the active substance actually enters the solution. This is a proxy for how the drug will be absorbed into the bloodstream. Specific limits for dissolution are usually found in the individual monograph for the specific drug substance. 4. Friability and Resistance to Crushing To most, it was an obscure file name

The majority of Monograph 0478 is dedicated to mandatory physical tests. Failure in any of these three categories results in batch rejection.

Ph. Eur. 2.9.3 While Disintegration tests physical breakdown, Dissolution tests bioavailability. Monograph 0478 states: "For conventional-release tablets, a dissolution test is carried out... unless a disintegration test is specified in the individual monograph."

To stay aligned with technological and regulatory advances, the European Pharmacopoeia Commission continuously refines its monographs. A major revision of Monograph 0478 was published in , becoming effective on January 1, 2018 . Key updates from this revision included: